
ASND
Ascendis Pharma A/S
$220.42
+$10.26(+4.88%)
75
Overall
--
Value
90
Tech
60
Quality
Market Cap
$11.93B
Volume
1.47M
52W Range
$118.03 - $229.94
Target Price
$258.13
Company Overview
| Mkt Cap | $11.93B | Price | $220.42 |
| Volume | 1.47M | Change | +4.88% |
| P/E Ratio | -31.6 | Open | $209.41 |
| Revenue | $363.6M | Prev Close | $210.16 |
| Net Income | $-378.1M | 52W Range | $118.03 - $229.94 |
| Div Yield | N/A | Target | $258.13 |
| Overall | 75 | Value | -- |
| Quality | 60 | Technical | 90 |
No chart data available
About Ascendis Pharma A/S
Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing TransCon-based therapies for unmet medical needs in Denmark, rest of Europe, North America, and internationally. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism. It also develops a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. Ascendis Pharma A/S was incorporated in 2006 and is headquartered in Hellerup, Denmark.
Sector: Healthcare
Industry: Biotechnology
Latest News
Stifel Nicolaus Remains a Buy on Ascendis Pharma (ASND)
TipRanks Auto-Generated Intelligence Newsdesk•18 days ago
Ascendis Pharma (ASND) Receives a Buy from Wells Fargo
TipRanks Auto-Generated Intelligence Newsdesk•18 days ago
FDA Calendar: These Are the Upcoming FDA Drug Approvals
Solomon Oladipupo•24 days ago
Ascendis Pharma (ASND) Receives a Buy from Wells Fargo
TipRanks Auto-Generated Intelligence Newsdesk•a month ago
Analysts Offer Insights on Healthcare Companies: Ascendis Pharma (ASND) and Alkermes (ALKS)
Catie Powers•a month ago
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | ASND | $220.42 | +4.9% | 1.47M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |